Zota Health Care (ZOTA) is loss-making over the last 12 months, losing ₹113 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹1,231.10, 29% below its 52-week high. Sales grew 57% a year over 3 years. Its dividend yield is 0.1%, and debt is 0.43× equity. It is a small-cap company with a market cap of ₹4,264 Cr, ranked 7th of 20 Biotechnology companies by market cap; the shares fell 22% over the past year.
- ₹1,225.00
- ₹1,250.00
- ₹1,202.20
- ₹1,218.80
- 30.3K
Health check
- ReturnsBehind
−21.9% over a year, better than 1 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthUnder pressure
Sales +56.7% a year over 3 years, but loss-making now.
- ProfitabilityNegative
ROCE -7.3% vs peer median 16.7%.
- Balance sheetStretched
Debt 0.43× equity, operating profit doesn’t cover interest, Piotroski 4 of 9.
- Red flags3 to check
Loss-making over the last twelve months.
Small cap
Defensive
Key metrics
- Market cap
- ₹4,264 Cr
- Small cap
- P/E
- n/a
- Industry 49.1
- Price to book
- 6.82
- Peers 4.52
- Dividend yield
- 0.08%
- ROE
- −24.1%
- Peers 14.3%
- ROCE
- −7.3%
- Peers 16.7%
- Debt to equity
- 0.43
- Debt ₹271 Cr
- EPS (TTM)
- −₹31.41
- Face value ₹10
- OPM (TTM)
- −0.4%
- Net margin −16.6%
- Sales growth
- +67.6%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 6.28
- EV/EBITDA −88.8
Strengths and risks
Strengths
- Quarterly sales up 67.6% on a year ago.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −24.1%.
- Interest coverage of only 1.3×.
About Zota Health Care
Zota Health Care Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company offers pharmaceutical, nutraceutical, ayurvedic, and over-the-counter products. It also provides various medicines for chronic ailments, such as diabetes, cardiac, and thyroid disorders. The company operates its retail stores under the DAVAINDIA name. Zota Health Care Limited was founded in 1995 and is headquartered in Surat,…
- Headquarters
- Surat
- Employees
- 635
- Sector
- Healthcare
- ISIN
- INE358U01012
- Website
- zotahealthcare.com
Price range
- Avg volume (3M)
- 1 L
- 1-year return
- minus 21.9%
- From 52-week high
- minus 29.2%
Peers · Biotechnology
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIOCONBiocon | 365.10 | plus 0.86% | 59,794 | 122.5 | 1.73 | 2.8% | 1.0% | 19.4% | 15.3% | −5.9% | 0.14% | minus 4.9% |
| ANTHEMAnthem Biosciences | 915.55 | plus 0.22% | 51,594 | 84.6 | 15.74 | 26.8% | 20.4% | 41.4% | 26.2% | 15.4% | 0.22% | plus 30.1% |
| ONESOURCEOnesource Specialty Pharma | 1,599.80 | plus 1.13% | 18,346 | – | 3.10 | 0.3% | 0.0% | 23.5% | 232.3% | – | 0.00% | minus 13.7% |
| CONCORDBIOConcord Biotech | 632.60 | minus 5.96% | 13,236 | 47.4 | 6.48 | 16.7% | 14.3% | 34.5% | 8.0% | 2.8% | 0.60% | minus 7.5% |
| BLUEJETBlue Jet Healthcare | 553.80 | minus 3.91% | 9,607 | 34.5 | 4.52 | 24.0% | 19.9% | 31.4% | 9.4% | 15.7% | 0.22% | minus 5.0% |
| SUPRIYASupriya Lifescience | 695.80 | minus 19.99% | 5,600 | 28.2 | 4.68 | 22.3% | 19.1% | 21.4% | 21.2% | 32.5% | 0.14% | plus 9.2% |
| ZOTAZota Health Care | 1,231.10 | plus 1.01% | 4,264 | – | 6.82 | −7.3% | −24.1% | 0.1% | 56.7% | – | 0.08% | minus 21.9% |
| DCALDishman Carbogen Amcis | 156.64 | minus 0.56% | 2,456 | 152.1 | 0.37 | 2.7% | 1.6% | 16.1% | 7.5% | – | 0.00% | minus 47.1% |
| Median of 7 peers | – | −0.56% | 13,236 | 66.0 | 4.52 | 16.7% | 14.3% | 23.5% | 15.3% | 15.4% | 0.14% | −5.0% |
Quarterly results
| ₹ Cr | Mar 25 | Jun 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 97.3 | 104 | 143 | 163 | 174 | |
| – | – | – | +67.7% | +67.6% | |
| 94.8 | 99.6 | 143 | 157 | 185 | |
| 2.5 | 4 | −0.4 | 5.9 | −11.6 | |
| 2.5% | 3.8% | −0.3% | 3.6% | −6.7% | |
| 1 | 0.9 | 1.7 | 6 | 2 | |
| 3.5 | 3.2 | 5 | 5.3 | 6.4 | |
| 14.3 | 14.7 | 22.3 | 27 | 27.7 | |
| – | – | – | −6 | – | |
| −14.3 | −13.1 | −26 | −26.4 | −43.7 | |
| 9.9% | −5.3% | −14.2% | 45.3% | −0.7% | |
| −12.9 | −14.3 | −29.5 | −14.2 | −43.6 | |
| -4.57 | -4.92 | -9.44 | -4.13 | -12.58 |
Profit & loss
- Sales CAGR 3Y
- +56.7%
- ROE
- −24.1%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 140 | 180 | 293 | 539 | |
| – | +29.0% | +62.3% | +83.9% | |
| 132 | 173 | 298 | 520 | |
| 8.1 | 7.6 | −4.9 | 18.3 | |
| 5.8% | 4.2% | −1.7% | 3.4% | |
| 1.1 | 0.7 | 0.3 | 4.5 | |
| 2.5 | 4.2 | 9 | 14.5 | |
| 12 | 20.2 | 43.2 | 82.5 | |
| 0.5 | −0 | −0.8 | −5.8 | |
| −4.7 | −16.2 | −57.6 | −79.8 | |
| −23.1% | 11.2% | 1.6% | 7.2% | |
| −5.8 | −14.3 | −56.4 | −73.9 | |
| -2.29 | -5.59 | -20.68 | -22.46 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 25.2 | 25.8 | 28.6 | 34.6 | |
| 55.2 | 64.1 | 195 | 659 | |
| 45.1 | 95.3 | 140 | 270 | |
| 32.6 | 43.1 | 75.9 | 167 | |
| 158 | 228 | 439 | 1,131 | |
| 60.9 | 103 | 187 | 366 | |
| 3.1 | 4.8 | 5.6 | 1.7 | |
| 7.5 | 4.7 | 54.4 | 264 | |
| 1.1 | 1 | 3.6 | 95.6 | |
| 85.5 | 114 | 189 | 403 | |
| 158 | 228 | 439 | 1,131 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −2 | −6 | −50 | −84.4 | |
| 14.7 | −12.9 | −92.2 | −314 | |
| −13.9 | 18.8 | 145 | 490 | |
| −1.2 | −0.1 | 2.6 | 92 | |
| −12.5 | −16.7 | −46 | −113 | |
| −14.5 | −22.7 | −95.9 | −197 | |
| −3.8 | −2.6 | −2.7 | −3.1 |
Shareholding pattern
NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 1.4% (Yahoo estimate).
Major shareholders
Filings & events
News
No recent news coverage found.